| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | F Xavier Pi-Sunyer | |
| Blandine Laferrère | |||
| Blanca Oliván | |||
| Julio Teixeira | |||
| Mousumi Bose | |||
| P2860 | cites work | Gastric emptying rate after gastric bypass and gastroplasty | Q68954077 |
| Gastric emptying after gastric bypass | Q69548064 | ||
| The effect of jejunoileal bypass on postprandial release of plasma gastric inhibitory polypeptide (GIP) | Q70199206 | ||
| Vertical banded gastroplasty for obesity | Q70329916 | ||
| Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells | Q70869265 | ||
| Insulin secretion, clearance and action before and after gastroplasty in severely obese subjects | Q72131697 | ||
| Methods for voluntary weight loss and control. NIH Technology Assessment Conference Panel. Consensus Development Conference, 30 March to 1 April 1992 | Q72907348 | ||
| The role of postprandial releases of insulin and incretin hormones in meal-induced satiety--effect of obesity and weight reduction | Q74287135 | ||
| Resolution of diabetes mellitus and metabolic syndrome following Roux-en-Y gastric bypass and a variant of biliopancreatic diversion in patients with morbid obesity | Q80259605 | ||
| How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and beta-cell function in Goto-kakizaki rats through an enhanced Proglucagon gene expression and L-cell number | Q80609084 | ||
| Ghrelin increases food intake in obese as well as lean subjects | Q81787195 | ||
| Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease | Q83334952 | ||
| Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses | Q93538767 | ||
| Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects | Q22250885 | ||
| Bariatric Surgery Utilization and Outcomes in 1998 and 2004: Statistical Brief #23 | Q26849446 | ||
| Glucagon receptors on human islet cells contribute to glucose competence of insulin release | Q28138830 | ||
| Inhibition of food intake in obese subjects by peptide YY3-36 | Q28204942 | ||
| The Physiology of Glucagon-like Peptide 1 | Q28373115 | ||
| Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis | Q28570314 | ||
| Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats | Q28578709 | ||
| Bariatric surgery: a systematic review and meta-analysis | Q30769299 | ||
| Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake | Q33669320 | ||
| Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans | Q33845996 | ||
| Overweight, obesity, and health risk | Q33890013 | ||
| Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery | Q33959262 | ||
| Role of adipose tissue in body-weight regulation: mechanisms regulating leptin production and energy balance | Q34039596 | ||
| Gut hormone PYY(3-36) physiologically inhibits food intake | Q34143493 | ||
| Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. | Q34325049 | ||
| Mechanisms in the development of type 2 diabetes mellitus | Q34500037 | ||
| Leptin signaling, adiposity, and energy balance | Q34524449 | ||
| The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes | Q34576196 | ||
| Effects of obesity surgery on non-insulin-dependent diabetes mellitus | Q34934028 | ||
| Bariatric surgery and long-term control of morbid obesity | Q35020501 | ||
| Enhancing Incretin Action for the Treatment of Type 2 Diabetes | Q35545683 | ||
| Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies | Q35649213 | ||
| Incretins, insulin secretion and Type 2 diabetes mellitus | Q35669308 | ||
| Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes | Q35772029 | ||
| Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus | Q35824086 | ||
| The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. | Q35866509 | ||
| Circulation and degradation of GIP and GLP-1. | Q36012469 | ||
| Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding | Q36259482 | ||
| Hormonal mechanisms of weight loss and diabetes resolution after bariatric surgery | Q36573716 | ||
| Short-term changes in insulin resistance following weight loss surgery for morbid obesity: laparoscopic adjustable gastric banding versus laparoscopic Roux-en-Y gastric bypass | Q47320711 | ||
| PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity | Q47325260 | ||
| Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters | Q47356520 | ||
| Circulating insulin-like growth factor I concentrations in clinically severe obese patients with and without NIDDM in response to weight loss | Q47368793 | ||
| Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats | Q47405665 | ||
| Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. | Q47790721 | ||
| A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut? | Q48030241 | ||
| Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. | Q48457433 | ||
| Laparoscopic adjustable gastric banding versus Roux-en-Y gastric bypass: 5-year results of a prospective randomized trial | Q48475675 | ||
| Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. | Q48714353 | ||
| Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: role of insulin sensitivity and beta cell function. | Q51168864 | ||
| Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. | Q51244259 | ||
| The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats. | Q51468040 | ||
| GLP-1 and changes in glucose tolerance following gastric bypass surgery in morbidly obese subjects. | Q51481151 | ||
| Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. | Q51488073 | ||
| Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. | Q51495618 | ||
| Peptide YY levels are elevated after gastric bypass surgery. | Q51500912 | ||
| Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. | Q51505083 | ||
| Short-term effects of gastric bypass surgery on circulating ghrelin levels. | Q51528468 | ||
| Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. | Q51581246 | ||
| Hyperinsulinism, glucose-dependent insulinotropic polypeptide, and the enteroinsular axis in morbidly obese patients before and after gastric bypass. | Q51632588 | ||
| Relationships Between Fasting Plasma Glucose Levels and Insulin Secretion During Intravenous Glucose Tolerance Tests | Q51671449 | ||
| Entero-endocrine changes after gastric bypass in diabetic and nondiabetic patients: a preliminary study. | Q51749947 | ||
| Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35. | Q53180211 | ||
| The effect of gastric bypass operation on glucose tolerance in obesity. | Q54459219 | ||
| Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells | Q58088431 | ||
| The Effect of Glucagon-Like Peptide I (GLP-I) on Glucose Elimination in Healthy Subjects Depends on the Pancreatic Glucoregulatory Hormones | Q58169355 | ||
| Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man | Q58449161 | ||
| Chronic PYY3–36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice | Q61037202 | ||
| Surgical treatment of obesity and its effect on diabetes: 10-y follow-up | Q67735582 | ||
| A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin | Q46447210 | ||
| Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study | Q46536937 | ||
| Ileal transposition controls diabetes as well as modified duodenal jejunal bypass with better lipid lowering in a nonobese rat model of type II diabetes by increasing GLP-1. | Q46562210 | ||
| Secretion and hepatic extraction of insulin after weight loss in obese noninsulin-dependent diabetes mellitus | Q46676321 | ||
| Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes | Q46689486 | ||
| Improvement of insulin resistance after obesity surgery: a comparison of gastric banding and bypass procedures | Q46720328 | ||
| Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release | Q46779245 | ||
| Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model. | Q46783348 | ||
| Gastric banding for the treatment of type 2 diabetes mellitus in morbidly obese. | Q46786609 | ||
| Restoration of acute insulin response in T2DM subjects 1 month after biliopancreatic diversion. | Q46788647 | ||
| Circulating peptide YY, weight loss, and glucose homeostasis after gastric bypass surgery in morbidly obese subjects | Q46793748 | ||
| Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance | Q46868130 | ||
| Peptide YY and glucagon-like peptide-1 in morbidly obese patients before and after surgically induced weight loss | Q46876009 | ||
| Effect of laparoscopic mini-gastric bypass for type 2 diabetes mellitus: comparison of BMI>35 and <35 kg/m2. | Q46947046 | ||
| Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal | Q46982079 | ||
| Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus | Q47205801 | ||
| Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas | Q47234077 | ||
| Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial | Q47234529 | ||
| Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study | Q47256275 | ||
| Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass | Q47263805 | ||
| Serum ghrelin, leptin and adiponectin levels before and after weight loss: comparison of three methods of treatment--a prospective study | Q47312330 | ||
| Incretins, diabetes, and bariatric surgery: a review | Q36573756 | ||
| New applications for endoscopy: the emerging field of endoluminal and transgastric bariatric surgery | Q36688499 | ||
| Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes | Q36755303 | ||
| Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes. | Q36816194 | ||
| Bariatric surgery: the past, present, and future | Q37027335 | ||
| The effect of laparoscopic gastric banding surgery on plasma levels of appetite-control, insulinotropic, and digestive hormones | Q37095586 | ||
| Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials | Q37187301 | ||
| Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes | Q37345249 | ||
| Banting lecture 1990. Beta-cells in type II diabetes mellitus | Q37633379 | ||
| Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice | Q38313572 | ||
| Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial | Q38392749 | ||
| Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. | Q39648063 | ||
| New developments in the incretin concept | Q39832287 | ||
| Weight and non-insulin-dependent diabetes mellitus | Q40979158 | ||
| Effects of a very-low-calorie diet on long-term glycemic control in obese type 2 diabetic subjects | Q41189471 | ||
| Intestinal adaptation after jejunoileal bypass in man | Q41822827 | ||
| Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes | Q42169660 | ||
| The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects | Q42436041 | ||
| Restoration of Euglycemia and Normal Acute Insulin Response to Glucose in Obese Subjects With Type 2 Diabetes Following Bariatric Surgery | Q42440397 | ||
| Changes in glucagon-like peptide-1 (GLP-1) secretion after biliopancreatic diversion or vertical banded gastroplasty in obese subjects | Q42476857 | ||
| Effects of weight loss and reduced hyperglycemia on the kinetics of insulin secretion in obese non-insulin dependent diabetes mellitus | Q42481296 | ||
| Glucagon-like peptide-1 7-36: a physiological incretin in man. | Q43623564 | ||
| Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulin-dependent diabetes mellitus | Q43626381 | ||
| Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients | Q43705651 | ||
| Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans | Q43766536 | ||
| The insulin tolerance test in morbidly obese patients undergoing bariatric surgery | Q43822500 | ||
| Serum leptin levels after bariatric surgery across a range of glucose tolerance from normal to diabetes | Q43844761 | ||
| Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study | Q43919658 | ||
| Laparoscopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three-year study. | Q44089003 | ||
| Improved beta-cell function after standardized weight reduction in severely obese subjects | Q44295533 | ||
| Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects | Q44392867 | ||
| Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect | Q44457682 | ||
| Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes | Q44467078 | ||
| One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial. | Q44563947 | ||
| Effect of Laparoscopic Roux-En Y Gastric Bypass on Type 2 Diabetes Mellitus | Q44609117 | ||
| Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease | Q44699316 | ||
| Insulin resistance in nondiabetic morbidly obese patients: effect of bariatric surgery. | Q44705311 | ||
| Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. | Q44764978 | ||
| Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells | Q44777018 | ||
| Malnutrition after gastric surgery. Association with exaggerated distal intestinal hormone release | Q44810736 | ||
| Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty | Q44969260 | ||
| The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism | Q44992657 | ||
| Effects of weight loss in obese subjects with normal fasting plasma glucose or impaired glucose tolerance on insulin release and insulin resistance according to a minimal model analysis | Q45034767 | ||
| Glycemic control in diabetic patients after bariatric surgery | Q45103166 | ||
| Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin | Q45105936 | ||
| Effects of very-low-calorie diet weight reduction on glucose tolerance, insulin secretion, and insulin resistance in obese non-insulin-dependent diabetics | Q45341787 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 217-229 | |
| P577 | publication date | 2008-09-27 | |
| P1433 | published in | Obesity Surgery | Q15762541 |
| P1476 | title | Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence? | |
| P478 | volume | 19 |
| Q22241093 | "Metabolic" Surgery for Treatment of Type 2 Diabetes Mellitus |
| Q37889178 | Advances in the etiology and management of hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass |
| Q41809362 | Bariatric surgery and T2DM improvement mechanisms: a mathematical model. |
| Q26783213 | Bariatric surgery and diabetes remission: Who would have thought it? |
| Q37241584 | Bariatric surgery and diabetes remission: sleeve gastrectomy or mini-gastric bypass? |
| Q84152703 | Bariatric surgery as treatment for type 2 diabetes |
| Q30391329 | Changes in neurohormonal gut peptides following bariatric surgery |
| Q34779258 | Comparison of different gastric bypass procedures in gastric carcinoma patients with type 2 diabetes mellitus |
| Q40642524 | Comparison of the effectiveness of four bariatric surgery procedures in obese patients with type 2 diabetes: a retrospective study |
| Q37697736 | Does the length of the biliary limb influence medium-term laboratory remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass in morbidly obese patients? |
| Q34748035 | Dual mechanism for type-2 diabetes resolution after Roux-en-Y gastric bypass |
| Q45986635 | Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptor-mediated mechanism. |
| Q34791792 | Dynamics of type 2 diabetes mellitus laboratory remission after Roux-en-Y gastric bypass in patients with body mass index lower than 35 kg/m(2) and higher than 35 kg/m(2) in a 3-year observation period. |
| Q44896182 | Early improvement in albuminuria in non-diabetic patients after Roux-en-Y bariatric surgery |
| Q34484580 | Effect of Modified Roux-en-Y Gastric Bypass Surgery on GLP-1, GIP in Patients with Type 2 Diabetes Mellitus |
| Q34469078 | Effect of gastrointestinal surgical manipulation on metabolic syndrome: a focus on metabolic surgery |
| Q51355601 | Effect of laparoscopic Roux-en-Y gastroenterostomy with BMI<35 kg/m(2) in type 2 diabetes mellitus. |
| Q42878278 | Effects of Subtotal Gastrectomy and Roux-en-Y Gastrojejunostomy on the Clinical Outcome of Type 2 Diabetes Mellitus |
| Q51291473 | Effects of gastric bypass on FoxO1 expression in the liver and pancreas of diabetic rats. |
| Q51378475 | Effects of sleeve gastrectomy and medical treatment for obesity on glucagon-like peptide 1 levels and glucose homeostasis in non-diabetic subjects. |
| Q36768111 | Effects of sleeve gastrectomy on parameters of lipid and glucose metabolism in obese women - 6 months after operation |
| Q50229806 | Epidermal growth factor can optimize a serum-free culture system for bone marrow stem cell proliferation in a miniature pig model |
| Q37515272 | Evaluation of Weight Loss Failure, Medical Outcomes, and Personal Experiences after Roux-en-Y Gastric Bypass: A Critical Analysis |
| Q37885717 | GLP-1 and energy balance: an integrated model of short-term and long-term control |
| Q37691668 | Gastric bypass and glucose metabolism |
| Q37428509 | Glucose homeostasis and weight loss in morbidly obese patients undergoing banded sleeve gastrectomy: a prospective clinical study |
| Q36084126 | Impact of Roux-en-Y gastric bypass on regulation of diabetes type 2 in morbidly obese patients |
| Q37421154 | Impact of Roux-en-Y gastric bypass surgery on rat intestinal glucose transport |
| Q51284538 | Impact of Sleeve Gastrectomy on Type 2 Diabetes Mellitus, Gastric Emptying Time, Glucagon-Like Peptide 1 (GLP-1), Ghrelin and Leptin in Non-morbidly Obese Subjects with BMI 30-35.0 kg/m2: a Prospective Study. |
| Q26744254 | Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different? |
| Q60934789 | Initial outcomes of one anastomosis gastric bypass at a single institution |
| Q52594787 | Intestinal and Gastric Origins for Diabetes Resolution After Bariatric Surgery. |
| Q36454360 | Isolated duodenal exclusion increases energy expenditure and improves glucose homeostasis in diet-induced obese rats |
| Q35529693 | Mechanisms responsible for excess weight loss after bariatric surgery |
| Q41999320 | Neuroendocrine mechanisms underlying bariatric surgery - insights from human studies and animal models. |
| Q38257429 | Nutrition and metabolic support recommendations for the bariatric patient |
| Q35054892 | Obesity surgery and gut-brain communication |
| Q41832470 | Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report |
| Q44949422 | Preoperative fasting plasma C-peptide level may help to predict diabetes outcome after gastric bypass surgery |
| Q38621964 | Recognition and management of hyperinsulinemic hypoglycemia after bariatric surgery |
| Q24563430 | Regulation of glucose homeostasis by GLP-1 |
| Q27022123 | Relationship between gut hormones and glucose homeostasis after bariatric surgery |
| Q43281624 | Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling? |
| Q34979966 | Role of the foregut in the early improvement in glucose tolerance and insulin sensitivity following Roux-en-Y gastric bypass surgery |
| Q37862878 | Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: understanding weight loss and improvements in type 2 diabetes after bariatric surgery. |
| Q51326499 | Short-term outcomes of laparoscopic single anastomosis gastric bypass (LSAGB) for the treatment of type 2 diabetes in lower BMI (<30 kg/m(2)) patients. |
| Q57116647 | Sleeve gastrectomy plus side-to-side jejunoileal anastomosis for the treatment of morbid obesity and metabolic diseases: a promising operation |
| Q51344499 | Sleeve gastrectomy with jejunal bypass for the treatment of type 2 diabetes mellitus in patients with body mass index <35 kg/m2. A cohort study. |
| Q38837956 | Surgical cure for type 2 diabetes by foregut or hindgut operations: a myth or reality? A systematic review |
| Q51277741 | The Effects of One-Anastomosis Gastric Bypass on Glucose Metabolism in Goto-Kakizaki Rats. |
| Q51359833 | The difference of glucostatic parameters according to the remission of diabetes after Roux-en-Y gastric bypass. |
| Q37144071 | The effect of duodenal-jejunal bypass on glucose-dependent insulinotropic polypeptide secretion in Wistar rats |
| Q33696549 | The environment within: how gut microbiota may influence metabolism and body composition |
| Q33932609 | The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass surgery |
| Q58612044 | The long term effect of metabolic profile and microbiota status in early gastric cancer patients after subtotal gastrectomy |
| Q30388925 | The neurohormonal regulation of energy intake in relation to bariatric surgery for obesity |
| Q51280064 | Type 2 Diabetes Mellitus remission eighteen months after Roux-en-Y gastric bypass. |
| Q43274874 | Usefulness of continuous glucose monitoring for the diagnosis of hypoglycemia after a gastric bypass in a patient previously treated for type 2 diabetes |
| Q37101249 | Vagal blocking improves glycemic control and elevated blood pressure in obese subjects with type 2 diabetes mellitus |
Search more.